Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
We propose a patient-tailored strategy that considers the risk for postoperative right heart failure, utilizing the percutaneous ProtekDuo cannula (Livanova, London, UK) in an innovative way to perform cardiopulmonary bypass during LVAD implantation in ECMO patients. Our novel protocol is based on the early intra-operative use of the ProtekDuo cannula, adopting the distal lumen as the pulmonary vent and the proximal lumen as the venous inflow cannula during cardiopulmonary bypass. This configuration is rapidly switched to the standard fashion to provide planned postoperative temporary right ventricular support, in selected patients at high risk of right ventricular failure. From September 2020 to June 2022, six patients were supported with the ProtekDuo cannula during and after an intracorporeal LVAD implantation (five of which were minimally invasive): four HeartMate III (Abbott, U.S.A.) and two HVAD (Medtronic Inc, MN). In all cases, the ProtekDuo cannula was correctly positioned and removed without complications after a median period of 8 days. Non-fatal bleeding (bronchial hemorrhage) occurred in one patient (17%) during biventricular support. Thirty-day mortality was 0%. From this preliminary work, our novel strategy demonstrated to be a feasible solution for planned minimally invasive right ventricular support in ECMO patients scheduled for a durable LVAD implantation.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9740870 | PMC |
| http://dx.doi.org/10.3390/jcm11237062 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Long Term Outcomes of Tricuspid Valve Repair or Replacement in Patients with Continuous Flow Left Ventricular Assist Devices.
J Thorac Cardiovasc Surg
September 2025
Division of Cardiac, Thoracic & Vascular Surgery, Department of Surgery, Columbia University Irving Medical Center, NewYork-Presbyterian Hospital, New York, NY. Electronic address:
Objective: Our objective was to determine the long-term outcomes of concomitant tricuspid valve procedures (TVP) during continuous-flow left ventricular assist device (LVAD) implantation.
Methods: We retrospectively reviewed patients who received HeartMate II or 3 from 2004 to 2023. Nine patients who had a previous TVP were excluded.
Safe Practices: Partial Coverage of Left Ventricular Assist Device Reduces Bleeding Risk during Explant-Heart Transplant without Causing Obstruction.
J Heart Lung Transplant
September 2025
Vanderbilt University Medical Center, Department of Cardiac Surgery, Nashville, TN. Electronic address:
Left ventricular assist device (LVAD) explantation is technically challenging during heart transplantation (HT) and is associated with intraoperative and postoperative blood loss. This single institution study examined the effects of partial polytetrafluoroethylene (PTFE) protective coverage during HeartMate 3 implant on perioperative blood loss during the explant-HT. We found that partial PTFE coverage of the outflow graft and chassis during HeartMate 3 implant is significantly associated with reduced intraoperative and postoperative transfusion requirements, and postoperative chest tube output.
View Article and Find Full Text PDFStrategic Approach Towards the Evaluation of HeartMate 3 Left Ventricular Assist Devices Using Multimodality Imaging.
Am J Cardiol
August 2025
Division of Cardiovascular Diseases and Hypertension, Rutgers University - Robert Wood Johnson Medical School, 125 Paterson Street, East Tower - 8th Floor, New Brunswick, New Jersey 08901, United States. Electronic address:
The use of left ventricular assist devices (LVADs) has increased in recent years as a destination therapy. The HeartMate 3 (HM3) is currently the only commercially available LVAD for implantation in the United States. Societal guidelines for multimodality cardiac imaging evaluation of LVADs and temporary mechanical support devices were recently published and serve as a comprehensive resource for the evaluation of LVAD patients.
View Article and Find Full Text PDFImpact of pump position on postoperative outcomes in less invasive left ventricular assist device implantation.
Front Cardiovasc Med
August 2025
Department of Cardiac Surgery and Research Group for Experimental Surgery, Medical Faculty and University Hospital Düsseldorf, Heinrich-Heine-University, Düsseldorf, Germany.
Introduction: less invasive approach (LIS) has recently become increasingly used for left ventricular assist device (LVAD) implantation. However, the impact of surgical access on pump position and clinical outcomes comparing LIS-LVAD implantation to full sternotomy (ST) has not been well discussed.
Methods: Between April 2010 and February 2021, a total of 237 consecutive patients received a LVAD, 76 (32.
Sympathectomy in refractory ventricular arrhythmias in patients with left ventricular assist device: a grand round case report.
Eur Heart J Case Rep
September 2025
Servicio de Cardiología, Hospital General Universitario Gregorio Marañón, Calle Doctor Esquerdo 46, 28007 Madrid, Spain.
Background: Ventricular tachycardias (VTs) are a life-threatening complication of patients with end-stage left ventricular dysfunction, and are a frequent cause for considering advanced therapies. Their management in patients supported by a left ventricular assist device (LVAD) presents unique challenges, requiring a multidisciplinary approach to tailored strategies.
Case Summary: We present the case of a 70-year-old male with a history of VTs who underwent HeartMate 3 (Abbott, USA) implantation for advanced heart failure secondary to ischaemic cardiomyopathy and refractory VTs.